FGF23 from bench to bedside
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is a strong association between elevated circulating fibroblast growth factor-23 (FGF23) levels and adverse outcomes in patients with chronic kidney disease (CKD) of all stages. Initially discovered as a regulator of phosphate and vitamin D homeostasis, FGF23 has now been implicated in several pathophysiological mechanisms that may negatively impact the cardiovascular and renal systems. FGF23 is purported to have direct (off-target) effects in the myocardium, as well as canonical effects on FGF receptor/α-klotho receptor complexes in the kidney to activate the renin-angiotensin-aldosterone system, modulate soluble α-klotho levels, and increase sodium retention, to cause left ventricular hypertrophy (LVH). Conversely, FGF23 could be an innocent bystander produced in response to chronic inflammation or other processes associated with CKD that cause LVH and adverse cardiovascular outcomes. Further exploration of these complex mechanisms is needed before modulation of FGF23 can become a legitimate clinical target in CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 2×
“Recent studies have suggested that FGF23 has a direct effect on cardiac myocytes independent of intermediates such as elevated blood pressure (22, 31).”
BackgroundSuppression of Aging in Mice by the Hormone Klotho
Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005) · Science · doi:10.1126/science.1112766 · Cited by 1,935
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733 · cited 1×
“ACE2 is a functional component of the renin-angiotensin system (RAS) that counteracts the effects of angiotensin II and participates in blood pressure regulation (35) and normal heart (18) and endothelial (96, 118) function.”
BackgroundReceptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164
Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21
Owen, B. M., Mangelsdorf, D. J., & Kliewer, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.10.002 · Cited by 286
Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., & Quarles, L. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-177816 · Cited by 254 · cited 1×
“FGF23 gene expression in bone is regulated by multiple factors, including 1,25(OH)2D, calcium, PTH, paracrine FGFs, sympathetic nervous system, bone mineralization (75), leptin, estrogen, and glucocorticoids (74, 113), and factors affecting Address for reprint requests and other correspondence: C.”
BackgroundSelf-citation
Cited by
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
FGF23 signalling and physiology
Ho, B. B., & Bergwitz, C. (2021) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0178 · Cited by 180
“…shown to reduce expression of angiotensinconverting enzyme 2 (ACE2), a component of the reninangiotensin system, and thus has been proposed to participate systemically in blood pressure regulation and to prevent angiotensin-related cardiac remodeling as recently reviewed (Kovesdy & Quarles 2016).”
BackgroundRadloff, J., Pagitz, M., Andrukhova, O., Oberbauer, R., Burgener, I. A., & Erben, R. G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.649921 · Cited by 23
“In addition, it has been reported that angiotensin II stimulates osteoblastic FGF23 secretion (Kovesdy and Quarles, 2016).”
BackgroundFGF23 in chronic kidney disease: Bridging the heart and anemia
Figurek, A., Rroji, M., & Spasovski, G. (2023) · Cells · doi:10.3390/cells12040609 · Cited by 22
Metadata
- Authors
- Kovesdy, C. P., & Quarles, L. D.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2016-06-01
- Volume
- 310
- Issue
- 11
- Pages
- F1168-F1174
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W2294844169
- Cited by
- 64
- References
- 6
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FGF23 from bench to bedside. https://app.cochat.ai/papers/10.1152/ajprenal.00606.2015
- The paper
- Kovesdy, C. P., & Quarles, L. D. (2016). FGF23 from bench to bedside. American Journal of Physiology-Renal Physiology. https://doi.org/10.1152/ajprenal.00606.2015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.